Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples